share_log

Vertex Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Bozic Carmen

Vertex Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Bozic Carmen

福泰製藥 | 4：持股變動聲明-高管 Bozic Carmen
美股SEC公告 ·  08/08 16:10
Moomoo AI 已提取核心訊息
Carmen Bozic, EVP and CMO of Vertex Pharmaceuticals Inc. (VRTX), completed a sale of 2,280 shares of common stock on August 7, 2024. The transaction was executed at a price of $476.75 per share, resulting in a total sale value of $1,086,990. Following the sale, Bozic's direct holdings in the company amount to 23,259 shares. The sale took place in an open market transaction, as reported by Vertex Pharmaceuticals.
Carmen Bozic, EVP and CMO of Vertex Pharmaceuticals Inc. (VRTX), completed a sale of 2,280 shares of common stock on August 7, 2024. The transaction was executed at a price of $476.75 per share, resulting in a total sale value of $1,086,990. Following the sale, Bozic's direct holdings in the company amount to 23,259 shares. The sale took place in an open market transaction, as reported by Vertex Pharmaceuticals.
福泰製藥（VRTX）的執行副總裁兼首席市場官Carmen Bozic於2024年8月7日完成了2,280股普通股的銷售交易。交易價格爲476.75美元每股，總銷售價值爲1,086,990美元。此次交易是在公開市場交易中完成的，Bozic在公司的直接持股總共有23,259股。據Vertex Pharmaceuticals報道。
福泰製藥（VRTX）的執行副總裁兼首席市場官Carmen Bozic於2024年8月7日完成了2,280股普通股的銷售交易。交易價格爲476.75美元每股，總銷售價值爲1,086,990美元。此次交易是在公開市場交易中完成的，Bozic在公司的直接持股總共有23,259股。據Vertex Pharmaceuticals報道。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息